Study of a radioactive drug for advanced solid tumors
Part of Cancer, Digestive system clinical trials.
This trial tests a new radioactive drug (Lutetium-177 BL-ARC001) for people with advanced solid tumors, including stomach, bowel, and other cancers. It aims to see if the treatment is safe and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a locally advanced or metastatic solid tumor (a cancer that has spread).
- You are at least 18 years old and in generally good health (able to do daily activities).
- Any side effects from prior treatments should be mild or resolved.
- You must be willing to provide a tumor sample (from a past biopsy or new sample).
- You must not have other serious medical conditions like active infections, heart problems, or another cancer in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive drug (177Lu-BL-ARC001) for people with advanced lung, breast, head and neck, or other solid tumors that have not responded to standard treatments. It aims to see if the drug can target and shrink tumors while limiting side effects.
This trial tests a new radioactive drug, Lutetium-177 FAP-75, for people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and deliver radiation directly to cancer cells, potentially slowing tumor growth.
This trial tests an investigational drug called BL-ARC002 for people with advanced or metastatic cancers of the esophagus, stomach, colon, rectum, or other solid tumors. The goal is to see if it is safe and effective in treating these cancers.
This early-stage trial tests a new cancer drug called BL-ARC002 in patients whose advanced or spread cancers (solid tumors) have not responded to standard treatments. The drug is an antibody designed to help the immune system fight cancer.
This early-phase study tests two new radioactive treatments (lutetium-177 and actinium-225) together with a guided imaging agent in people with GRPR-positive solid tumors (including prostate, breast, or colorectal cancers). The goal is to see if these treatments can shrink tumors that have stopped responding to standard therapies.
This trial tests a new radioactive drug, 177Lu-SN201, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors and to find the best dose.
Hear when a new Gastrointestinal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.